LifeMine Therapeutics Inc.

https://www.lifeminetx.com

LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery. LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on advancing highly impactful precision medicines in oncology and immune modulation. The Company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D., and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou. Headquartered in Cambridge, Mass., and with a second site at Gloucester Harbor, Mass., LifeMine has raised more than $295 million from leading life science investors. *

	Start	2017-01-01 established
	Group	LifeMine Therapeutics (Group)
	Industry	AI-based drug discovery / AI-based drug development
	Industry 2	genomics
	Person	Klausner, Richard (Rick) (Lyell Immunopharma 201910 CEO + Founder before Juno Therapeutics + NCI)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	30 Acorn Park Drive Cambridge Discovery Park
	City	02140 Cambridge, MA
		Address record changed: 2022-06-26

Basic data	Employees	n. a.

		* Document for »About Section«: LifeMine Therapeutics Inc.. (3/23/22). "Press Release: LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance". Cambridge, MA.

		Record changed: 2023-07-10